| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
56,030,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kronos Bio is a late-stage clinical development biopharmaceutical company, with a focus on developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. Co.'s primary product candidate, entospletinib, is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor. Co. is also developing lanraplenib, its orally-administered SYK inhibitor. In addition, Co. is developing KB-0742, its internally discovered, oral cyclin dependent kinase 9 inhibitor, for the treatment of MYC-amplified and other transcriptionally addicted solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,731,056 |
1,731,056 |
2,328,185 |
| Total Buy Value |
$0 |
$1,470,394 |
$1,470,394 |
$3,721,479 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
3 |
3 |
6 |
| Total Shares Sold |
31,509 |
88,959 |
116,028 |
169,293 |
| Total Sell Value |
$33,207 |
$104,531 |
$151,964 |
$246,344 |
| Total People Sold |
3 |
6 |
7 |
7 |
| Total Sell Transactions |
3 |
8 |
11 |
16 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dinsmore Christopher |
Chief Scientific Officer |
• – – |
2021-08-02 |
4 |
OE |
$3.27 |
$30,048 |
D/D |
9,189 |
105,549 |
|
- |
|
| De Backer Marianne |
Director |
– • – |
2021-05-28 |
4 |
B |
$25.01 |
$15,006 |
D/D |
600 |
600 |
2.39 |
- |
|
| Loven Jakob |
Director |
– • – |
2021-04-20 |
4 |
AS |
$20.10 |
$433,185 |
I/I |
(21,551) |
1,301,537 |
|
- |
|
| Loven Jakob |
Director |
– • – |
2021-04-19 |
4 |
AS |
$20.25 |
$288,278 |
I/I |
(14,004) |
1,323,088 |
|
- |
|
| Loven Jakob |
Director |
– • – |
2021-04-16 |
4 |
AS |
$20.84 |
$696,762 |
I/I |
(33,162) |
1,337,092 |
|
- |
|
| Loven Jakob |
Director |
– • – |
2021-04-15 |
4 |
AS |
$21.78 |
$540,536 |
I/I |
(24,818) |
1,370,254 |
|
- |
|
| Loven Jakob |
Director |
– • – |
2021-04-14 |
4 |
AS |
$22.38 |
$744,029 |
I/I |
(32,636) |
1,395,072 |
|
- |
|
| Loven Jakob |
Director |
– • – |
2021-04-13 |
4 |
AS |
$23.35 |
$405,793 |
I/I |
(17,020) |
1,427,708 |
|
- |
|
| Loven Jakob |
Director |
– • – |
2021-04-12 |
4 |
AS |
$26.27 |
$415,896 |
I/I |
(15,828) |
1,444,728 |
|
- |
|
| Loven Jakob |
Director |
– • – |
2021-04-09 |
4 |
AS |
$27.20 |
$589,152 |
I/I |
(21,660) |
1,460,556 |
|
- |
|
| Loven Jakob |
Director |
– • – |
2021-04-08 |
4 |
AS |
$27.09 |
$1,730,487 |
I/I |
(63,128) |
1,482,216 |
|
- |
|
| Bischofberger Norbert W |
President & CEO |
• • – |
2020-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
198,124 |
198,124 |
|
- |
|
| Dinsmore Christopher |
Chief Scientific Officer |
• – – |
2020-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
91,110 |
96,360 |
|
- |
|
| Kosacz Barbara |
COO & General Counsel |
• – – |
2020-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
69,824 |
684,424 |
|
- |
|
| Dimartino Jorge |
Chief Medical Officer & VP |
• – – |
2020-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
133,937 |
133,937 |
|
- |
|
| Al-Wakeel Yasir B. |
Chief Financial Officer |
• – – |
2020-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
72,422 |
109,641 |
|
- |
|
| Belldegrun Rebecka |
Director |
– • – |
2020-10-14 |
4 |
A |
$0.00 |
$0 |
I/I |
423,738 |
679,575 |
|
- |
|
| Martin John C |
Director |
– • – |
2020-10-14 |
4 |
B |
$19.00 |
$1,440,200 |
I/I |
75,800 |
1,952,364 |
2.1 |
- |
|
| Martin John C |
Director |
– • – |
2020-10-14 |
4 |
A |
$0.00 |
$3,314,949 |
I/I |
1,876,564 |
1,876,564 |
|
- |
|
| Kosacz Barbara |
COO & General Counsel |
• – – |
2020-10-14 |
4 |
B |
$19.00 |
$99,750 |
D/D |
5,250 |
614,600 |
2.74 |
- |
|
| Loven Jakob |
Director |
– • – |
2020-10-14 |
4 |
A |
$0.00 |
$2,729,851 |
I/I |
1,545,344 |
1,545,344 |
|
- |
|
| Belldegrun Arie |
Director |
– • – |
2020-10-14 |
4 |
A |
$0.00 |
$4,090,004 |
I/I |
2,739,052 |
2,315,314 |
|
- |
|
| Dinsmore Christopher |
Chief Scientific Officer |
• – – |
2020-10-14 |
4 |
B |
$19.00 |
$99,750 |
D/D |
5,250 |
5,250 |
2.74 |
- |
|
| Tanen David M |
Director |
– • – |
2020-10-14 |
4 |
A |
$0.00 |
$599,472 |
I/I |
339,355 |
471,230 |
|
- |
|
| Tanen David M |
Director |
– • – |
2020-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
231,553 |
363,428 |
|
- |
|
97 Records found
|
|
Page 3 of 4 |
|
|
